China Survey of Stress Ulcer Bleeding in Critically Ill Neurosurgical Patients (SUP)

February 27, 2017 updated by: AstraZeneca

Stress ulcers or stress-related mucosal disease (SRMD) is defined as "acute superficial inflammation lesions of the gastric mucosa induced when an individual is subject to abnormally elevated physiologic demands."[1] Studies have shown that SRMD occurred in 75%-100% ICU patients[1]. Gastrointestinal bleeding due to SRMD is an important complication in critically ill patients. The frequency of clinically important bleeding ranged from 5.3% to 33%.[2] The mortality in ICU patients with stress related bleeding approaches 50%, which is much higher than the patients without bleeding (9%). [3] In 1999, the American Society of Health-System Pharmacists (ASHP) published guidelines on the use of stress ulcer prophylaxis in medical, surgical, respiratory, and pediatric ICU patients [2]. PPIs and H2RA are widely used in China current clinical practice for the prevention of stress ulcer bleeding. However, there is no epidemiology data to show the risk factors for stress ulcer bleeding and the bleeding rate of Chinese neurosurgical critically ill patients who are usually suffering from brain trauma, cerebral haemorrhage or brain tumour operation. Information is needed to know about the characteristics in Chinese critically ill neurosurgical patients.

Objectives of this Non-Interventional Study Primary

  1. Primary objective: To estimate the overall incidence of upper gastrointestinal (GI) bleeding in critically ill neurosurgical patients in China.
  2. Main secondary objective

    • To estimate the incidence of upper GI bleeding with clinically significant complications in critically ill neurosurgical patients in China.
    • To estimate the incidence of any overt upper GI bleeding without clinically significant complications in critically ill neurosurgical patients in China.
    • To assess time to upper GI bleeding after a cerebral lesion.
    • To investigate potential risk factors associated with upper GI bleeding, and assess how common certain risk factors occurred in upper GI bleeding patients.
    • To assess the overall incidence of upper GI bleeding in critically ill patients by different risk factors for upper GI bleeding.
    • To investigate the drugs, the route of administration, the doses and the duration commonly used for stress ulcer prophylaxis.
    • To investigate the proportion of ICU patients with nasogastric tube, and the duration of nasogastric tube.

(ICU: Intensive care unit PPIs: Proton pump inhibitors H2RA: H2 receptor antagonist)

Study Overview

Study Type

Observational

Enrollment (Actual)

1416

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Beijing
      • Beijing, Beijing, China
        • Research Site
    • Fujian
      • Fuzhou, Fujian, China
        • Research Site
    • Hebei
      • Tangshan, Hebei, China
        • Research Site
    • Hunan
      • Changsha, Hunan, China
        • Research Site
    • Jilin
      • Changchun, Jilin, China
        • Research Site
    • Shandong
      • Jinan, Shandong, China
        • Research Site
    • Shanghai
      • Shanghai, Shanghai, China
        • Research Site
    • Shanxi
      • Xi'an, Shanxi, China
        • Research Site
    • Sichuan
      • Chengdu, Sichuan, China
        • Research Site
    • Tianjin
      • Tianjin, Tianjin, China
        • Research Site
    • Zhejiang
      • Hangzhou, Zhejiang, China
        • Research Site

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

The subject population that will be included in the NIS are the consecutive discharged patients ≥18 years old who were hospitalized to Neurosurgical departments and whose GCS≤10[4] within 24 hours of lesion/admission. The subjects will be focused on brain trauma, cerebral haemorrhage or postoperative brain tumour population.

Description

Inclusion Criteria:

  • The subject population that will be included in the NIS are the consecutive discharged patients ≥18 years old who were hospitalized to Neurosurgical departments. Those whose Glasgow Coma Scale (GCS) ≤10[4] within 24 hours of lesion/admission will be defined as critically ill patients. Three kinds of cases will be included: brain trauma critically ill patients, cerebral haemorrhage critically ill patients or postoperative brain tumour critically ill patients.

Exclusion Criteria:

  • If participating in any clinical trial, the subject cannot take part in this study. Subjects are ineligible if they have below conditions:

    1. Those who were likely to swallow blood (for example, those with severe facial trauma or epistaxis;
    2. Patients with previous total gastrectomy;
    3. Known upper GI lesions that might bleed (e.g., varices, polyps, tumours, etc);
    4. Evidence of active GI bleeding including oesophageal and gastric variceal bleeding, Peptic Ulcer Disease (PUD)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
patients ≥18 ,Neurosurgical departments and whose GCS≤10[4]

The subject population that will be included in the NIS are the consecutive discharged patients ≥18 years old who were hospitalized to Neurosurgical departments and whose GCS≤10[4] within 24 hours of lesion/admission.(GCS: Glasgow Coma Scale NIS: Non-Interventional Study

)

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
The primary variable is the overall incidence of upper GI bleeding in critically ill neurosurgical patients
Time Frame: during the first 14 days (up to 14 days) after the cerebral lesion (trauma, haemorrhage or postoperative).
during the first 14 days (up to 14 days) after the cerebral lesion (trauma, haemorrhage or postoperative).

Secondary Outcome Measures

Outcome Measure
Time Frame
The incidence of upper GI bleeding with clinically significant complications in critically ill neurosurgical patients
Time Frame: during the first 14 days (up to 14 days) after the cerebral lesion (trauma, haemorrhage or postoperative).
during the first 14 days (up to 14 days) after the cerebral lesion (trauma, haemorrhage or postoperative).

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

January 1, 2015

Primary Completion (Actual)

July 1, 2015

Study Completion (Actual)

July 1, 2015

Study Registration Dates

First Submitted

December 11, 2014

First Submitted That Met QC Criteria

December 11, 2014

First Posted (Estimate)

December 15, 2014

Study Record Updates

Last Update Posted (Actual)

February 28, 2017

Last Update Submitted That Met QC Criteria

February 27, 2017

Last Verified

February 1, 2017

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • D1843R00056

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Stress Ulcers

3
Subscribe